Lippo-backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia


The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through it\'s affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with Preneticsâ„¢, a Personalized & Precision Medicine Life Sciences company based in Hong Kong. Under the terms of the MoU, Venturra Capital will invest an un-disclosed amount in the USD millions into Prenetics.
The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through it's affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with Prenetics™, a Personalized & Precision Medicine Life Sciences company based in Hong Kong. Under the terms of the MoU, Venturra Capital will invest an un-disclosed amount in the USD millions into Prenetics.
In addition, the Lippo Group will act as a strategic partner for an initial period of 5-Years to offer personalized & precision medicine in Indonesia. Prenetics has developed its proprietary iGenes Pharmacogenomics test. Pharmacogenomics is the study of how genes affects a person's response to drugs. iGenes is a non-invasive, saliva based test with a report ready to physicians within 48 hours. The iGenes report will identify the right drug, at the right dosage, tailored to a patient's genetic make-up.
$213 billion in avoidable and unnecessary healthcare costs, affects millions of people (USA)Prenetics also Announces World-Class Scientific, Medical and Commercial Advisory Board

© 2023 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com